1	Serum biomarkers and anti-flavivirus antibodies at presentation as indicators of severe
2	dengue
3	
4	Running Title: Serum biomarkers of severe dengue
5	
6	Cynthia Bernal ^{1*} and Sara Ping ^{2*} , Alejandra Rojas ¹ , Oliver Caballero ¹ , Victoria Stittleburg ² ,
7	Yvalena de Guillén ¹ , Patricia Langjahr ³ , Benjamin A. Pinsky ^{4,5} , Marta Von-Horoch ⁶ , Patricia
8	Luraschi ⁶ , Sandra Cabral ⁶ , María Cecilia Sánchez ⁷ , Aurelia Torres ⁷ , Fátima Cardozo ^{1,7†,#} and
9	Jesse J. Waggoner ^{2,8†,#}
10	
11	¹ Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud, San
12	Lorenzo, Paraguay
13	² Emory University School of Medicine, Division of Infectious Diseases, Atlanta, GA, USA
14	³ Universidad Nacional de Asunción, Facultad de Ciencias Químicas, San Lorenzo, Paraguay
15	⁴ Department of Pathology, Stanford University School of Medicine, California, USA
16	⁵ Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford
17	University School of Medicine, California, USA
18	⁶ Hospital Central - Instituto de Previsión Social, Departamento de Epidemiología, Asunción,
19	Paraguay
20	⁷ Hospital Central - Instituto de Previsión Social, Departamento de Laboratorio de Análisis
21	Clínicos, Asunción, Paraguay
22	⁸ Rollins School of Public Health, Department of Global Health, Atlanta, GA, USA

23 Abstract

24 Background

Dengue is the most common vector-borne viral disease worldwide. Most cases are mild, but some
evolve into severe dengue (SD), with high lethality. Therefore, it is important to identify
biomarkers of severe disease to improve outcomes and judiciously utilize resources.

28

29 Methods/Principal Findings

30 One hundred forty-five confirmed dengue cases (median age, 42; range <1-91 years), enrolled 31 from February 2018 to March 2020, were selected from an ongoing study of suspected arboviral 32 infections in the Asunción metropolitan area. Cases included dengue virus types 1, 2, and 4, and severity was categorized according to the 2009 World Health Organization guidelines. Serologic 33 and biomarker (lipopolysaccharide binding protein and chymase) testing were performed on acute-34 phase samples by ELISA; additional serologic testing was performed with the multiplex pGOLD 35 36 assay. Complete blood counts and chemistries were performed at the discretion of the care team. 37 Age, gender, and pre-existing comorbidities were associated with SD vs. dengue with/without 38 warning signs in logistic regression with odds ratios (ORs) of 1.06 (per year; 95% confidence 39 interval, 1.02, 1.10), 0.12 (female; 0.03,0.5), and 9.82 (presence; 1.92, 50.24) respectively. In 40 binary logistic regression, for every unit increase in anti-DENV IgG in the pGOLD assay, odds of 41 SD increased by 2.54 (1.19-5.42). Platelet count, lymphocyte percent, and elevated chymase were 42 associated with SD in a combined logistic regression model with ORs of 0.99 (1,000/µL; 43 0.98,0.999), 0.92 (%; 0.86,0.98), and 1.17 (mg/mL; 1.03,1.33) respectively.

44

45 Conclusions

- 46 Multiple, readily available factors were associated with SD in this population. These findings
- 47 will aid in the early detection of potentially severe dengue cases and inform the development of
- 48 new prognostics for use in acute-phase and serial samples from dengue cases.

49 Author Summary

50 Dengue fever is an acute disease caused by dengue virus and transmitted to humans through the 51 bite of infected Aedes mosquitoes. Dengue is the most common vector-borne viral disease 52 worldwide affecting an estimated 50-100 million people and with 10,000 dengue-related deaths each year. Currently, there is no specific treatment, and safe and effective vaccines have not been 53 54 fully implemented. Most dengue cases present with nonspecific mild symptoms, but some will evolve into severe dengue, which can be fatal. Early detection and subsequent timely treatment 55 56 have been shown to decrease mortality among severe cases. Therefore, it is very important to 57 identify biomarkers for the early identification of cases at risk for progression to severe disease. In this study we analyze demographic factors, clinical laboratory data, lipopolysaccharide 58 binding protein and chymase to evaluate associations with disease severity. This study was 59 carried out in Paraguay, which is a hyperendemic country for dengue where the disease has been 60 61 understudied. A number of factors were found to be associated with severe disease in this population, including patient age, male gender, presence of comorbid illnesses, low platelet 62 63 count, low lymphocyte percentage, and elevated chymase level.

64 Introduction

Dengue is a common acute febrile illness in tropical and subtropical regions of the world and 65 66 accounts for upwards of 10% of such illnesses in areas of endemicity [1-3]. Each year, an estimated 67 50-100 million dengue cases and 10,000 dengue-related deaths occur worldwide, resulting from 68 infection with one of the four types of dengue virus (DENV, genus *Flaviviridae*) [1, 3, 4]. Dengue 69 severity ranges dramatically from a mild subclinical illness to dengue fever and clinically severe 70 dengue with plasma leakage, hemorrhage, and/or end-organ dysfunction [1, 3, 5, 6]. Timely 71 diagnosis and the initiation of appropriate supportive care improves clinical outcomes and can 72 lower mortality in clinically severe dengue from 20% to <1% [1, 3, 7, 8]. Although clinically 73 severe cases represent a minority of dengue cases overall, fatal and hospitalized non-fatal cases 74 account for over half of the \$8.9 billion USD annual economic burden of dengue [6, 9]. Therefore, early identification of cases at increased risk for developing clinically severe dengue could both 75 76 improve clinical outcomes and alleviate the economic burden caused by dengue on resource 77 constrained medical systems [10].

78

Clinically severe dengue results from a complex interplay of virus [11-14], host [15-22], and 79 80 epidemiologic factors [1, 6, 15]. The manifestations of severe dengue also differ based on patient 81 age, with children more commonly developing plasma leakage compared to hemorrhage in adults [6, 23, 24]. Studies have identified associations between the detection and/or concentration of 82 83 various molecules or gene transcripts and severe dengue [25-30]. One group of biomarkers that 84 has been studied are proteins released during mast cell degranulation: vascular endothelial growth 85 factor (VEGF) and the proteases tryptase and chymase [31-41]. In studies of patients from South and Southeast Asia, chymase was associated with and predictive of the development of clinically 86

87 severe dengue [31, 32, 34, 35, 38]. Chymase release from mast cells occurs in the presence of 88 DENV and may be increased by pre-existing anti-DENV IgG antibodies or blocked by antibodies against viral non-structural protein 1 (NS1) [33, 42]. Lipopolysaccharide (LPS) and 89 90 lipopolysaccharide binding protein (LBP) are another set of molecules that have higher levels in 91 dengue cases compared to healthy controls and in clinically severe cases compared to dengue 92 fever, which could indicate their usefulness as a predictor of severity [43-46]. Elevated levels of 93 circulating LPS and LBP result from derangements in gut permeability, potentially leading to 94 bacterial translocation, bacteremia, and worsened outcomes. Finally, numerous clinical laboratory 95 findings have been associated with clinically severe dengue, such as thrombocytopenia, 96 lymphopenia, and evidence of liver or kidney injury [13, 17, 24, 46-48]. These may either define cases as clinically severe with end-organ dysfunction or predict the development of severe dengue 97 98 through detection of changes over the course of illness [3].

99

100 The objective of the current study was to evaluate biomarkers of dengue severity among 101 participants enrolled in an ongoing study of acute arboviral illness in the metropolitan area of 102 Asunción, Paraguay. Paraguay is hyperendemic for dengue, with sustained viral circulation since 103 1999 and large disease outbreaks occurring every 2-5 years. In 2018, predominant circulation of 104 DENV-1 was recorded [49], and in 2019-2020, this shifted to DENV-4, resulting in the largest 105 outbreak in the country's history [50]. Previous studies from Paraguay have found an increased 106 risk of clinically severe dengue with DENV-2 and secondary infections [51-53]. However, dengue, 107 and in particular biomarkers of severe disease, remains understudied in the country [54, 55]. 108 Previously, our group evaluated anti-DENV and anti-ZIKV NS1 IgG levels among dengue cases 109 in 2018 using a multiplex serological assay, the pGOLD assay [56]. Anti-DENV IgG levels in the

pGOLD assay correlated with focus reduction neutralization test (FRNT50) titers, and an association was observed between hospitalization and detection of both anti-DENV and anti-ZIKV IgG. However, hospitalization is an inexact measure of clinical dengue severity. Therefore, in the current study, we sought to evaluate this earlier finding and levels of chymase and LBP as indicators of dengue severity among participants categorized according to the 2009 World Health Organization guidelines [3].

116

117

118 Methods

119 Ethics statement

The study protocol was reviewed and approved by the Scientific and Ethics Committee of the
Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (IICSUNA, IRB00011984), and the Emory University Institutional Review Board (IRB00000569).
A written consent was obtained from all the participants, or alternatively an oral consent.

124

125 Clinical samples

Individuals included in the current study were enrolled in an ongoing parent study of suspected
arboviral infections in the Asunción metropolitan area between February 2018 and March 2020.
Participants of both genders and all ages were enrolled as outpatients at IICS-UNA in all study
years and in the emergency care/inpatient facilities of Hospital Villa Elisa, 2018, and Hospital
Central of the Instituto de Previsión Social, 2019-2020. Inclusion criteria for the parent study
were an acute illness including two or more of the following symptoms: fever (measured or
subjective), red eyes, rash, joint pain involving more than one joint, and/or diffuse muscle pain.

Patients with fever and no other localizing signs or symptoms were also included. Day 1 wasdefined as the first day of symptoms.

135

136 One hundred forty-five participants with acute dengue and up to 7 days of symptoms were 137 selected for the current analysis. Cases were classified according to the 2009 WHO criteria as 138 dengue without warning signs (DWS-), dengue with warning signs (DWS+) and severe dengue 139 (SD) [3]. For categorization as DWS+, it was necessary to have at least one warning sign. For 140 categorization as SD, an individual had to develop at least one criterion for SD during the 141 clinical course. To maximize study power, all SD cases in the parent study were included in this 142 analysis. A mixture of DWS- and DWS+ cases was then selected to achieve a representative 143 distribution of participants based on age, days of symptoms, comorbidities, and gender from 144 across the study period and to maintain an even distribution of these two categories.

145

146 Laboratory testing

147 Acute-phase serum or plasma samples were collected at study enrollment and transported to the 148 IICS-UNA laboratory. Samples were tested for DENV NS1 antigen using the Standard Q 149 Dengue Duo rapid immunochromatographic test (SD Biosensor, Suwon, South Korea) according 150 to manufacturer recommendations. Qualitative antibody data acquired using this method was not 151 evaluated in this study, see antibody section below. Primary samples were then aliquoted and 152 stored at -80°C until later use or shipment on dry ice to Emory University for additional testing. 153 For molecular testing, total nucleic acids were extracted from 200µL of sample on an EMAG instrument and eluted into 50µL of buffer. Samples were tested for Zika virus, chikungunya 154 155 virus and DENV by real-time RT-PCR (rRT-PCR) using a validated and published multiplex

156	assay (the ZCD assay) [57], and DENV serotype and viral load were determined with a
157	published DENV multiplex assay [58, 59]. Both rRT-PCRs were performed as previously
158	described [57-59].

159

160 Serologic testing was performed on acute-phase samples using two different methods. First, anti-161 DENV IgG and IgM were analyzed using commercial ELISA kits [Dengue ELISA IgG (G1018)] 162 and Dengue ELISA IgM Capture (M1018), Vircell Microbiologists, Granada, Spain] according to 163 manufacturer recommendations (interpretation: IgM or IgG index >11 positive, 9-11 164 indeterminate, <9 negative). Second, a 5µL aliquot of serum from 139 participants with sufficient 165 sample was tested in the pGOLD assay (Nirmidas Biotech, Inc, Palo Alto, CA), which is a 166 multiplex serological assay for IgM and IgG against DENV (DENV-2 whole virus antigen) and ZIKV (NS1 antigen). The pGOLD assay was performed as previously described [56, 60]. In each 167 168 well of the pGOLD slide, antigens are spotted in triplicate, and average signals are used during 169 analysis. For IgG, the negative control signal was subtracted from the sample signal, and the 170 difference was divided by the average signal of four IgG control spots included in each well. For 171 IgM, a similar calculation was performed using the signal from a known anti-DENV IgM positive 172 control sample included on each run. A positive threshold ratio of 0.1 was established for each 173 isotype, which was ≥ 3 standard deviations above the mean of the negative control.

174

175 Chymase and LBP levels were determined using commercial ELISA kits (G-Biosciences, St.
176 Louis, MO, USA), following the manufacturer's instructions. Complete blood counts and
177 chemistries were performed at the clinical site at the discretion of the care team, and results were
178 included if the sample was obtained within ±1 day of enrollment.

179

180 Case definitions

181 Dengue cases were defined as individuals who met inclusion criteria for the parent study and had

- 182 1) detectable DENV RNA in the ZCD and/or DENV multiplex rRT-PCR, 2) detection of DENV
- 183 NS1 by rapid test, or 3) a strong epidemiologic link (one patient, DWS-).

184

185 Statistical analysis

Basic statistical analyses were performed using Excel software (Microsoft, Redmond, WA). 186 187 Comparisons between group means and medians were made by the ANOVA, Welch's test, both 188 pooled and non-pooled two sample t-tests, and Kruskal Wallis tests. Comparisons of proportions 189 were made using chi-squared tests or Fisher exact tests (if the expected number in each cell was 190 <5). Graphs were prepared with GraphPad Prism version 9 (GraphPad, San Diego, CA). Crude 191 associations, statistical analysis and modeling were performed using SAS version 9.4. To calculate 192 odds ratios for SD, domain models were developed using demographic (age, gender, 193 comorbidities) and laboratory variables (basic clinical laboratory results, DENV viral load, 194 chymase and LBP). Models were evaluated using binomial logistic regression (DWS-/DWS+ vs. 195 SD). Significance was set at two-sided p-value ≤ 0.05 for all analyses.

196

197

198 Results

Demographic and clinical information. Of 145 participants in this study, 55 were categorized
as DWS-, 67 as DWS+, and 23 as SD. Demographic data and DENV diagnostic test results are
shown in Table 1 (binary categories) and Table S1 (three categories). Participants were enrolled

202	primarily at Hospital Central of the Instituto de Previsión Social (n=124), followed by Hospital
203	Villa Elisa (15) and IICS-UNA (6). Results for DWS- and DWS+ were not significantly different
204	for most analyses performed in this study. As such, results are reported for analyses using the
205	binary outcome of DWS-/DWS+ vs. SD, except where indicated. Data and analyses for the three
206	individual categories are provided in the Supplemental Material.

207

208 Table 1. Demographic data and DENV diagnostic test results for participants stratified by

209 dengue severity.

	DWS-/DWS+	SD	
Characteristic ^a	N=122	N=23	p-value
Age, years, mean (st. dev.)	34 (18)	61 (18)	<0.001
Gender, female	81 (66.4)	6 (26.1)	<0.001
$\overline{\text{Comorbidities}}, \geq 1^{\text{b}}$	31 (25.8)	16 (84.2)	<0.001
Days of symptoms, mean (st. dev.)	3.9 (1.9)	4.8 (1.7)	0.033
Year of Collection			0.015
2018	14 (11.5)	4 (17.4)	
2019	42 (34.4)	1 (4.3)	
2020	66 (54.1)	18 (78.3)	
DENV rRT-PCR, positive	110 (90.2)	20 (90.9)	1.00
Serotype			0.45
DENV-1	14 (12.7)	4 (20.0)	
DENV-2	9 (8.2)	0 (0)	
DENV-4	86 (78.2)	16 (80.0)	

Negative	1 (0.9)	0 (0)	
NS1, positive	77 (63.1)	21 (91.3)	0.010

- 210 Abbreviations: st. dev., standard deviation
- 211 ^a Presented as n (%) unless stated otherwise

^b Comorbidities: hypertension, 32; diabetes, 14; other, 30. Comorbidity data missing for DWS+
(2) and SD (4).

214

215	SD cases were significantly older than non-SD cases and were significantly more likely to be
216	male and have at least one comorbidity (Table 1). In logistic regression of these variables in
217	relation to disease severity, age, gender, and comorbidities remained in the model and were
218	predictors of severity with a strong goodness of fit (C statistic=0.93; Table 2). In addition, SD
219	cases presented for care later in the course of illness than non-severe cases (Table 1), and more
220	SD cases were included 2020, consistent with the large DENV-4 outbreak that occurred in
221	Paraguay that year [61].

222

Table 2. Binomial logistic regression of participant demographics and disease severity.

	SD vs. DWS-/DWS+		
Characteristic	OR	95% CI	
Age, years	1.06	1.02, 1.10	
Gender, female	0.12	0.03, 0.50	
Comorbidity, presence	9.82	1.92, 50.24	

224 Abbreviations: CI, confidence interval; OR, odds ratio

225

226 **DENV testing**

- 227 One hundred forty-four of 145 dengue cases (99.3%) tested positive by rRT-PCR, NS1 rapid
- test, or both; and only one case was included based epidemiologic criteria alone. Over 90% of
- 229 cases tested positive for DENV by rRT-PCR, and this did not differ between severity categories
- 230 (Table 1 and Table S1). The proportion of DWS-/DWS+ cases with detectable NS1 (77/122,
- 63.1%) was significantly lower than SD cases (21/23, 91.3%; p=0.010). DENV-4 was the

predominant type, present in 78.5% of the typed samples overall (102/130).

233

234 Acute-phase samples were tested with two serologic tests: the pGOLD assay for anti-DENV and

anti-ZIKV IgM and IgG, and a commercial ELISA for anti-DENV IgM and IgG (Table 3 and

- Table S2). The proportion of individuals with detectable anti-DENV IgM was significantly
- higher with the pGOLD assay (p<0.001, Table S3). Although a smaller proportion of SD cases
- had detectable anti-DENV IgM compared to DWS-/DWS+ cases by either method, this
- 239 difference only reached significance for the pGOLD assay. Most participants had detectable anti-
- 240 DENV IgG by either method: 120/139 (86.3%) in the pGOLD, 128/145 (88.3%) by commercial
- ELISA. The proportion of individuals with detectable anti-DENV IgG did not differ significantly
- by severity category (Table 3 and Table S2) or test method (p=0.07, Table S3).
- 243
- **Table 3.** Serologic test results stratified by disease severity.

Serologic Test	DWS-/DWS+a	SD ^a	p-value
pGOLD ^b			

DENV IgM	71/119 (59.7%)	7/20 (35.0%)	0.040
DENV IgG	102/119 (85.7%)	18/20 (90.0%)	1.00
ZIKV IgM	5/119 (4.2%)	0/20 (0%)	1.00
ZIKV IgG	19/119 (16.0%)	4/20 (20.0%)	0.52
ELISA			
DENV IgM	40/122 (32.8%)	5/23 (21.7%)	0.40
DENV IgG	106/122 (86.9%)	22/23 (95.7%)	1.00

245 a Presented as positive/tested (%)

^b pGOLD testing was performed on 139 participants with sufficient serum available

248 The pGOLD assay yields a quantitative result that correlates with DENV neutralizing titers [56].

249 In crude binary logistic regression, for every unit increase in anti-DENV IgG, the odds of SD

increased by a factor of 2.54 (95% CI, 1.19-5.42). No association was found between

251 quantitative anti-DENV IgM results and disease severity in crude binary logistic regression.

252

253 Clinical laboratory data

254 Mean values for most routine laboratory tests, LBP, and chymase differed significantly between

255 DWS-/DWS+ and SD cases (Fig 1, Table S4). Laboratory values were similar between DWS-

- and DWS+ cases except for platelet count, which demonstrated a stepwise decrease from DWS-
- to DWS+ to SD, and serum glutamic oxaloacetic transaminase (SGOT) and LBP, which

258 increased across severity categories (Fig S1, Table S5). DENV viral load did not differ by

259 severity category.

Fig 1. A-I) Clinical laboratory test result distributions by disease severity. J-L) Potential markers
of disease severity measured in the current study: J) lipopolysaccharide binding protein (LBP),
K) chymase, and L) DENV viral load by disease category. Bars on all graphs represent mean and
standard deviation. Labels on the graphs indicate the following: ns, not significant, p>0.05; *,
p≤0.05; **, p≤0.01; ***, p≤0.001; ****, p≤0.0001.



266

267	Routine laboratory tests were obtained at the discretion of the clinical care team, and as a result,
268	many participants were missing data, particularly for analytes in the metabolic panel: creatinine
269	(n=75 cases with results), bilirubin (76), and SGOT (84). Due to this fact, crude associations
270	with SD were calculated for all variables by binomial regression (Table 4), and variables
271	evaluated in the laboratory domain multivariable logistic regression were limited to lymphocyte
272	percent, platelet count, hematocrit, LBP, and chymase. These analytes displayed crude
273	associations with SD and had a sufficient number of data points to not compromise model
274	strength. In the binary logistic regression model, lymphocyte percent, platelet count, and
275	chymase were found to be associated with SD with a very good model fit (C statistic, 0.95; Table
276	5).

277

Table 4. Crude associations between laboratory results and dengue severity from binomiallogistic regression.

Laboratory Value	DWS-/DWS+a	SD ^a	OR for SD ^b
Bilirubin (mg/dL)	0.49±0.26	2.51±2.11	29.03 (3.74, 225.04)
Blood Creatinine (mg/dL)	0.85±0.22	3.76±2.29	372.71 (4.38, >999)
Chymase (mg/mL)	1.2±5.8	30.0±28.9	1.12 (1.06, 1.18)
Hematocrit (%)	39.4±4.5	35.9±8.2	0.89 (0.82, 0.97)
LBP (1,000 ng/mL)	11,917±5,030	18,766±5,510	1.28 (1.11, 1.40)
Leukocytes (1,000 /µL)	4,692±2,155	12,192±10,765	1.43 (1.19, 1.71)

Lymphocyte Percentage (%)	30.6±17.9	12.6±10.1	0.89 (0.84, 0.94)
Platelets (1,000 /µL)	152,462±72,110	68,364±60,249	0.98 (0.97, 0.99)
SGOT (IU/L)	58.0±45.2	102.8±66.6	1.02 (1.00, 1.03)

- 280 ^a Displayed as mean ± standard deviation
- 281 ^b Presented as odds ratio for SD (95% CI) vs. DWS-/DWS+
- 282
- **Table 5.** Binomial logistic regression model of laboratory results and disease severity.

	SD vs. DWS-/DWS+	
Variable	OR	95% CI
Lymphocyte, %	0.92	0.86, 0.98
Platelet count, 1,000/µL ^a	0.987	0.975, 0.999
Chymase, mg/mL	1.17	1.03, 1.33

284 Abbreviations: CI, confidence interval; OR, odds ratio

285 ^a Three decimal places shown for clarity

286

287 Chymase and SD

288 Mean chymase level was significantly higher among individuals with comorbidities (11.42, st.

dev. 22.55) compared to those without (2.35, 9.83; p=0.011). Notably, the single DWS- case

- with an elevated chymase level (Figs 1K and S1K) occurred in an individual with systemic lupus
- erythematosus. To evaluate for a potential interaction between chymase and comorbidities on the
- development of SD, logistic regression was performed including these two variables. Interaction
- 293 product terms were nonsignificant in binomial and multinomial models. Together, comorbidities

309	Discussion
308	
307	model fit C statistic=0.93).
306	level of anti-ZIKV NS1 IgM (0.02 in this population), the chymase OR was 1.21 (1.09, 1.34;
305	no detectable anti-ZIKV NS1 IgM, the chymase OR was 1.10 (1.04, 1.17), whereas at the mean
304	binomial linear regression such that as IgM increased, the chymase OR increased as well. With
303	regression for SD. However, anti-ZIKV NS1 IgM showed effect modification of chymase in
302	no interaction was observed between anti-ZIKV NS1 IgG and chymase in binomial linear
301	between chymase level and the quantitative anti-ZIKV NS1 IgM or IgG by linear regression, and
300	pGOLD assay, were investigated for their association with SD. There was no association
299	interactions between chymase and cross-reactive anti-ZIKV NS1 antibodies, detected in the
298	Anti-NS1 antibodies may modulate chymase release by mast cells in acute dengue, and
297	
296	goodness of fit (C statistic=0.95).
295	chymase had an OR of 1.12 (1.05, 1.18) (controlling for comorbidities). This model had a strong
294	had an OR of 17.91 (2.75, 116.63) for binomial logistic regression (controlling for chymase);

In a predominantly adult population of dengue cases in Paraguay, multiple factors were
associated with clinically severe dengue, including patient (age, gender, comorbidities), serologic
(elevated anti-DENV IgG), and laboratory variables (low platelet count, relative lymphopenia,
and elevated chymase).

314

315 Factors identified in the current study are generally consistent with the published dengue

316 literature. Although clinically severe dengue often occurs among children [1, 3, 24], age among

317 adults has been identified as a risk factor for poor outcomes, [17, 23, 46]. Adults are more likely 318 to develop severe bleeding, and this may be more difficult to manage than plasma leakage, for 319 which judicious fluid replacement is often effective [3, 6, 8, 17, 23, 24, 46]. Comorbid illness, 320 including poorly-controlled diabetes mellitus (hemoglobin A1c > 7%) and renal disease, have 321 been associated with SD [16, 18], and hypertension has also been identified in certain studies 322 [18]. A gender difference among clinically severe dengue has varied across studies [1, 6, 13, 17, 323 18]. In our population, 66.4% of DWS-/DWS+ cases were female in comparison to only 26.1% 324 of SD cases, and this difference remained significant after controlling for age and comorbidities. 325 Although dengue is often associated with leukopenia [3, 24, 62-64], SD cases in the current 326 study had a mild leukocytosis with reduced lymphocyte percentage (and a resulting neutrophil 327 predominance). Thrombocytopenia is a common finding in SD cases and was one of the few 328 factors that demonstrated a stepwise change across disease severity categories (DWS-, DWS+, 329 and SD) [1, 3, 17, 18, 24, 38, 62].

330

331 Chymase and LBP were evaluated as two markers of clinically severe dengue based on data from 332 their use in South and Southeast Asia [31, 32, 34, 35, 38, 42-44]. Both demonstrated a crude 333 association with SD compared to DWS-/DWS+. Although LBP did not remain in the final 334 laboratory domain model, it demonstrated a stepwise increase across the categories of severity, 335 which may have limited power in this study to identify a significant difference in a binomial 336 model. Chymase, along with other mast cell degranulation factors, has been associated with 337 clinically severe dengue in several studies [32-35], and the current study confirmed this finding 338 among dengue cases in Paraguay. As clinically severe dengue appears to be more common in 339 Southeast Asia relative to the Americas [2, 65], it is important to study potential differences in

340	pathophysiology between these regions and confirm markers of severity between populations.
341	Chymase release from mast cells may be modulated by specific anti-DENV antibodies. In mice,
342	pre-treatment with anti-DENV IgG increased chymase release in an FC γ RIII-dependent manner
343	[33], and in culture, anti-NS1 IgG blocked chymase release [42]. In the current study, we
344	observed an interaction between chymase level and antibodies against the NS1 protein of ZIKV,
345	a closely related flavivirus. Further evaluation of this interaction using an array of DENV NS1
346	proteins may delineate a mechanism of protection for anti-NS1 antibodies, which demonstrate
347	epitope-specific protection or enhancement [66, 67].
348	
349	Higher levels of anti-DENV IgG and undetectable anti-DENV IgM in the pGOLD multiplex
350	serologic assay were also associated with SD in our study population. These serologic results are
351	consistent with findings in secondary dengue cases, though this is difficult to determine with
352	certainty in acute-phase samples [3, 68]. Quantitative anti-DENV IgG levels in the pGOLD
353	assay correlate with DENV $FRNT_{50}$, and we previously observed that higher levels are
354	associated with hospitalization in dengue cases [56]. This finding was confirmed in the current
355	study when applying more consistent criteria for clinically severe dengue [3] and controlling for
356	day post-symptom onset (data not shown). However, simultaneous detection of anti-ZIKV NS1
357	IgG did not increase the risk for SD in contrast to our earlier findings [56]. Anti-DENV IgM
358	detection in the pGOLD proved more sensitive than a commercial ELISA and demonstrated little
359	cross-reactivity on the ZIKV NS1 antigen. Notably, interpretation of these results required the
360	use of a control sample that previously tested positive for anti-DENV IgM, and inclusion of a
361	calibrator with this assay would improve generalizability.

362

363 DENV serum viral load was not associated with SD in this cross-sectional study. Viral load 364 decreases rapidly over the first week post-symptom onset, and viral kinetics differ between 365 primary and secondary dengue [12, 69-77]. It is therefore difficult to capture peak viremia in 366 most clinical settings. With only a single data point for each patient in our study, the lack of 367 association between viral load and SD is not unexpected, but this highlights a potential limitation 368 of using viral load as a predictor of severity.

369

370 Difficulties in studying predictors of clinically severe dengue stem from the low proportion of 371 severe cases among all DENV infections, lack of rapid and accurate diagnostics, and variability 372 in the definition of study endpoints [3, 5, 6, 10]. The current study relied principally on DENV 373 rRT-PCR for diagnosis, with a subset of participants detected by NS1. As part of the parent study 374 design, participants typically presented with fever, which may bias this group toward more 375 severe cases [49, 78]. Nonetheless, seven factors were associated with clinically severe dengue: five of these are commonly available at the acute visit (age, gender, comorbidities, platelet count, 376 377 and lymphocyte percentage) and chymase and anti-DENV IgG can be measured by ELISA. 378 Study designs that enroll participants based on rapid antigen test results limit the sample size 379 necessary to include enough severe cases, but this may bias the study population given the 380 clinical performance of current rapid tests [3, 25, 49, 79, 80]. However, as many pathways 381 associated with clinically severe dengue appear linked to NS1, including chymase release and 382 development of specific antibodies, improved antigen diagnostics may increase DENV detection, 383 provide prognostic information, and facilitate future studies of clinically severe dengue [12, 14, 384 29, 42, 76].

385

386 This study had several limitations. First, a single acute-phase sample was available for each 387 participant. Samples were obtained at different timepoints in relation to the development of 388 severe disease among the participants, such that the study was not designed to prospectively 389 evaluate each marker as a predictor of clinically severe dengue. Second, although all available 390 SD cases were included, the sample size was small, particularly for the detection of differences 391 among factors with relatively narrow value ranges, such as quantitative pGOLD values. Third, 392 routine labs were collected at the discretion of the care team, and as a result, not all participants 393 had laboratory values within the correct time frame. This limited the variables included in the 394 laboratory domain multivariable analysis. 395

Among dengue cases in Paraguay caused by DENV-1, -2, and -4, age, gender, pre-existing
comorbidities, elevated anti-DENV IgG, thrombocytopenia, relative lymphopenia, and elevated
chymase were associated with SD. These findings will aid in the early detection of potentially
severe dengue cases and inform the development of new prognostics for use in acute-phase and
serial samples from dengue cases.

401 Acknowledgements

- 402 We thank the members of the study team based at the Instituto de Investigaciones en Ciencias de
- 403 la Salud, Universidad Nacional de Asunción; Hospital Villa Elisa; and Hospital Central del
- 404 Instituto de Provisón Social, all located in Paraguay, for their dedication to this study and their
- 405 excellent work. We are grateful to the study participants and their families.

406 **References**

407 1. Guzman MG, Harris E. Dengue. Lancet. 2015;385(9966):453-65. doi: 10.1016/S0140-6736(14)60572-9.
408 PubMed PMID: 25230594.

L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel TA, et al. Symptomatic Dengue in Children
in 10 Asian and Latin American Countries. The New England journal of medicine. 2016;374(12):1155-66. Epub
2016/03/24. doi: 10.1056/NEJMoa1503877. PubMed PMID: 27007959.

412 3. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. France:
 413 WHO Press; 2009.

414 4. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of
415 dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet Infectious diseases. 2016;16(6):712416 23. doi: 10.1016/S1473-3099(16)00026-8. PubMed PMID: 26874619; PubMed Central PMCID:

417 PMCPMC5012511.

5. Rosenberger KD, Alexander N, Martinez E, Lum LCS, Dempfle CE, Junghanss T, et al. Severe dengue
categories as research endpoints-Results from a prospective observational study in hospitalised dengue patients.
PLoS neglected tropical diseases. 2020;14(3):e0008076. Epub 2020/03/05. doi: 10.1371/journal.pntd.0008076.
PubMed PMID: 32130212; PubMed Central PMCID: PMCPMC7055818 following competing interests: Dr. Wills
reports personal fees from Takeda Vaccines Inc, outside the submitted work, for her work as a member of the Data
Monitoring Committee for their dengue vaccine trials. None of the other authors had anything to disclose.

424 6. Sharp TM, Anderson KB, Katzelnick LC, Clapham H, Johansson MA, Morrison AC, et al. Knowledge
425 gaps in the epidemiology of severe dengue impede vaccine evaluation. The Lancet Infectious diseases.
426 2022;22(2):e42-e51. Epub 2021/07/16. doi: 10.1016/S1473-3099(20)30871-9. PubMed PMID: 34265259.

427 7. Moraes GH, de Fatima Duarte E, Duarte EC. Determinants of mortality from severe dengue in Brazil: a
428 population-based case-control study. The American journal of tropical medicine and hygiene. 2013;88(4):670-6. doi:
429 10.4269/ajtmh.11-0774. PubMed PMID: 23400577; PubMed Central PMCID: PMC3617850.

8. Rocha C, Silva S, Gordon A, Hammond SN, Elizondo D, Balmaseda A, et al. Improvement in hospital
indicators after changes in dengue case management in Nicaragua. The American journal of tropical medicine and
hygiene. 2009;81(2):287-92. PubMed PMID: 19635885.

433 9. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a
434 systematic analysis. The Lancet Infectious diseases. 2016. doi: 10.1016/S1473-3099(16)00146-8. PubMed PMID:
435 27091092.

436 10. Robinson M, Einav S. Towards Predicting Progression to Severe Dengue. Trends Microbiol.
437 2020;28(6):478-86. Epub 2020/01/27. doi: 10.1016/j.tim.2019.12.003. PubMed PMID: 31982232.

438 11. Rico-Hesse R. Dengue virus evolution and virulence models. Clinical Infectious Diseases. 2007;44:1462.

Tricou V, Minh NN, Farrar J, Tran HT, Simmons CP. Kinetics of viremia and NS1 antigenemia are shaped
by immune status and virus serotype in adults with dengue. PLoS neglected tropical diseases. 2011;5(9):e1309.

441 13. Guilarde AO, Turchi MD, Siqueira JB, Jr., Feres VC, Rocha B, Levi JE, et al. Dengue and dengue
442 hemorrhagic fever among adults: clinical outcomes related to viremia, serotypes, and antibody response. The Journal
443 of infectious diseases. 2008;197(6):817-24. Epub 2008/02/14. doi: 10.1086/528805. PubMed PMID: 18269315.

Libraty DH, Young PR, Pickering D, Endy TP, Kalayanarooj S, Green S, et al. High circulating levels of
the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue

hemorrhagic fever. The Journal of infectious diseases. 2002;186(8):1165-8. doi: 10.1086/343813. PubMed PMID: 12355369.

448 15. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for dengue hemorrhagic
449 fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection.
450 Archives of virology. 2013;158(7):1445-59. Epub 2013/03/09. doi: 10.1007/s00705-013-1645-3. PubMed PMID:
451 23471635.

452 16. Lee IK, Hsieh CJ, Lee CT, Liu JW. Diabetic patients suffering dengue are at risk for development of
453 dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic
454 control on dengue severity. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
455 2020;53(1):69-78. Epub 2018/08/28. doi: 10.1016/j.jmii.2017.12.005. PubMed PMID: 30146413.

456 17. Pinto RC, Castro DB, Albuquerque BC, Sampaio Vde S, Passos RA, Costa CF, et al. Mortality Predictors
457 in Patients with Severe Dengue in the State of Amazonas, Brazil. PloS one. 2016;11(8):e0161884. Epub 2016/08/27.
458 doi: 10.1371/journal.pone.0161884. PubMed PMID: 27564084; PubMed Central PMCID: PMCPMC5001629.

18. Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Furuya-Kanamori L, Wangdi K. Clinical predictors of
severe dengue: a systematic review and meta-analysis. Infect Dis Poverty. 2021;10(1):123. Epub 2021/10/11. doi:
10.1186/s40249-021-00908-2. PubMed PMID: 34627388; PubMed Central PMCID: PMCPMC8501593.

462 19. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, et al. Antibody-dependent
463 enhancement of severe dengue disease in humans. Science. 2017;358(6365):929-32. Epub 2017/11/04. doi:
464 10.1126/science.aan6836. PubMed PMID: 29097492; PubMed Central PMCID: PMCPMC5858873.

465 20. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue
466 virus correlate with protection from symptomatic infection in a longitudinal cohort. Proceedings of the National
467 Academy of Sciences of the United States of America. 2016;113(3):728-33. doi: 10.1073/pnas.1522136113.
468 PubMed PMID: 26729879.

Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, et al.
Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature. 2018;557(7707):719Epub 2018/05/26. doi: 10.1038/s41586-018-0157-4. PubMed PMID: 29795354; PubMed Central PMCID:
PMCPMC6064976.

473 22. Waggoner JJ, Katzelnick LC, Burger-Calderon R, Gallini J, Moore RH, Kuan G, et al. Antibody474 Dependent Enhancement of Severe Disease Is Mediated by Serum Viral Load in Pediatric Dengue Virus Infections.
475 The Journal of infectious diseases. 2020;221(11):1846-54. Epub 2020/04/03. doi: 10.1093/infdis/jiz618. PubMed
476 PMID: 32236481; PubMed Central PMCID: PMCPMC7213574.

477 23. Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: lessons and challenges.
478 Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
479 2003;27(1):1-13. Epub 2003/05/03. doi: 10.1016/s1386-6532(03)00010-6. PubMed PMID: 12727523.

480 24. Hammond SN, Balmaseda A, Perez L, Tellez Y, Saborio SI, Mercado JC, et al. Differences in dengue
481 severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. The American journal of
482 tropical medicine and hygiene. 2005;73(6):1063-70. Epub 2005/12/16. PubMed PMID: 16354813.

483 25. Robinson M, Sweeney TE, Barouch-Bentov R, Sahoo MK, Kalesinskas L, Vallania F, et al. A 20-Gene Set
484 Predictive of Progression to Severe Dengue. Cell Rep. 2019;26(5):1104-11 e4. Epub 2019/01/31. doi:
485 10.1016/j.celrep.2019.01.033. PubMed PMID: 30699342; PubMed Central PMCID: PMCPMC6352713.

486 26. Assuncao-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, et al. Contribution of
487 macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J. 2010;24(1):218-28.
488 Epub 2009/09/25. doi: 10.1096/fj.09-139469. PubMed PMID: 19776337.

489 27. Jeewandara C, Gomes L, Udari S, Paranavitane SA, Shyamali NL, Ogg GS, et al. Secretory phospholipase
490 A2 in the pathogenesis of acute dengue infection. Immun Inflamm Dis. 2017;5(1):7-15. Epub 2017/03/03. doi:
491 10.1002/iid3.135. PubMed PMID: 28250920; PubMed Central PMCID: PMCPMC5322161.

492 28. Jeewandara C, Gomes L, Wickramasinghe N, Gutowska-Owsiak D, Waithe D, Paranavitane SA, et al.
493 Platelet activating factor contributes to vascular leak in acute dengue infection. PLoS neglected tropical diseases.
494 2015;9(2):e0003459. Epub 2015/02/04. doi: 10.1371/journal.pntd.0003459. PubMed PMID: 25646838; PubMed
495 Central PMCID: PMCPMC4315531.

29. Chen HR, Chao CH, Liu CC, Ho TS, Tsai HP, Perng GC, et al. Macrophage migration inhibitory factor is
critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability. PLoS pathogens.
2018;14(4):e1007033. Epub 2018/04/28. doi: 10.1371/journal.ppat.1007033. PubMed PMID: 29702687; PubMed
Central PMCID: PMCPMC6044858.

S00 30. Chen HR, Chuang YC, Lin YS, Liu HS, Liu CC, Perng GC, et al. Dengue Virus Nonstructural Protein 1
Induces Vascular Leakage through Macrophage Migration Inhibitory Factor and Autophagy. PLoS neglected
tropical diseases. 2016;10(7):e0004828. Epub 2016/07/15. doi: 10.1371/journal.pntd.0004828. PubMed PMID:
27409803; PubMed Central PMCID: PMCPMC4943727.

504 31. Furuta T, Murao LA, Lan NT, Huy NT, Huong VT, Thuy TT, et al. Association of mast cell-derived VEGF
505 and proteases in Dengue shock syndrome. PLoS neglected tropical diseases. 2012;6(2):e1505. Epub 2012/03/01.
506 doi: 10.1371/journal.pntd.0001505. PubMed PMID: 22363824; PubMed Central PMCID: PMCPMC3283553.

507 32. St John AL, Rathore AP, Raghavan B, Ng ML, Abraham SN. Contributions of mast cells and vasoactive
508 products, leukotrienes and chymase, to dengue virus-induced vascular leakage. Elife. 2013;2:e00481. Epub
509 2013/05/03. doi: 10.7554/eLife.00481. PubMed PMID: 23638300; PubMed Central PMCID: PMCPMC3639510.

510 33. Syenina A, Jagaraj CJ, Aman SA, Sridharan A, St John AL. Dengue vascular leakage is augmented by mast
511 cell degranulation mediated by immunoglobulin Fcgamma receptors. Elife. 2015;4. Epub 2015/03/19. doi:
512 10.7554/eLife.05291. PubMed PMID: 25783751; PubMed Central PMCID: PMCPMC4362203.

513 34. Tissera H, Rathore APS, Leong WY, Pike BL, Warkentien TE, Farouk FS, et al. Chymase Level Is a
514 Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. The Journal of infectious
515 diseases. 2017;216(9):1112-21. Epub 2017/10/03. doi: 10.1093/infdis/jix447. PubMed PMID: 28968807; PubMed
516 Central PMCID: PMCPMC5853622.

517 35. Rathore APS, Senanayake M, Athapathu AS, Gunasena S, Karunaratna I, Leong WY, et al. Serum chymase
518 levels correlate with severe dengue warning signs and clinical fluid accumulation in hospitalized pediatric patients.
519 Scientific reports. 2020;10(1):11856. Epub 2020/07/18. doi: 10.1038/s41598-020-68844-z. PubMed PMID:
520 32678248; PubMed Central PMCID: PMCPMC7367272.

521 36. King CA, Wegman AD, Endy TP. Mobilization and Activation of the Innate Immune Response to Dengue
522 Virus. Front Cell Infect Microbiol. 2020;10:574417. Epub 2020/11/24. doi: 10.3389/fcimb.2020.574417. PubMed
523 PMID: 33224897; PubMed Central PMCID: PMCPMC7670994.

524 37. Sherif NA, Zayan AH, Elkady AH, Ghozy S, Ahmed AR, Omran ES, et al. Mast cell mediators in relation
525 to dengue severity: A systematic review and meta-analysis. Rev Med Virol. 2020;30(1):e2084. Epub 2019/11/12.
526 doi: 10.1002/rmv.2084. PubMed PMID: 31709696.

527 38. Sahu AK, Aggarwal P, Ekka M, Nayer J, Bhoi S, Kumar A, et al. Assessing the serum chymase level as an
528 early predictor of dengue severity. Journal of medical virology. 2021;93(6):3330-7. Epub 2020/08/29. doi:
529 10.1002/jmv.26468. PubMed PMID: 32857465.

530 39. Seet RC, Chow AW, Quek AM, Chan YH, Lim EC. Relationship between circulating vascular endothelial
 growth factor and its soluble receptors in adults with dengue virus infection: a case-control study. International

journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2009;13(5):e248-53. Epub 2009/03/06. doi: 10.1016/j.ijid.2008.11.028. PubMed PMID: 19261502.

534 40. Srikiatkhachorn A, Ajariyakhajorn C, Endy TP, Kalayanarooj S, Libraty DH, Green S, et al. Virus-induced
535 decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic
536 Fever. Journal of virology. 2007;81(4):1592-600. Epub 2006/12/08. doi: 10.1128/JVI.01642-06. PubMed PMID:
537 17151115; PubMed Central PMCID: PMCPMC1797579.

41. Patra G, Saha B, Mukhopadhyay S. Study of serum VEGF levels in patients with severe dengue infection
admitted in a tertiary care hospital in Kolkata. Journal of medical virology. 2019;91(10):1873-6. Epub 2019/06/28.
doi: 10.1002/jmv.25529. PubMed PMID: 31243775.

541 42. Chu YT, Wan SW, Chang YC, Lee CK, Wu-Hsieh BA, Anderson R, et al. Antibodies against nonstructural
542 protein 1 protect mice from dengue virus-induced mast cell activation. Lab Invest. 2017. Epub 2017/02/28. doi:
543 10.1038/labinvest.2017.10. PubMed PMID: 28240747.

43. van de Weg CA, Koraka P, van Gorp EC, Mairuhu AT, Supriatna M, Soemantri A, et al.
Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2012;53(1):38-42.
Epub 2011/10/22. doi: 10.1016/j.jcv.2011.09.028. PubMed PMID: 22014848.

548 44. van de Weg CA, Pannuti CS, de Araujo ES, van den Ham HJ, Andeweg AC, Boas LS, et al. Microbial
549 translocation is associated with extensive immune activation in dengue virus infected patients with severe disease.
550 PLoS neglected tropical diseases. 2013;7(5):e2236. Epub 2013/05/30. doi: 10.1371/journal.pntd.0002236. PubMed
551 PMID: 23717702; PubMed Central PMCID: PMCPMC3662706.

552 45. Kamaladasa A, Gomes L, Jeewandara C, Shyamali NL, Ogg GS, Malavige GN. Lipopolysaccharide acts
553 synergistically with the dengue virus to induce monocyte production of platelet activating factor and other
554 inflammatory mediators. Antiviral research. 2016;133:183-90. Epub 2016/08/01. doi:
555 10.1016/j.antiviral.2016.07.016. PubMed PMID: 27476044.

46. Lee IK, Liu JW, Yang KD. Clinical and laboratory characteristics and risk factors for fatality in elderly
patients with dengue hemorrhagic fever. The American journal of tropical medicine and hygiene. 2008;79(2):14953. Epub 2008/08/12. PubMed PMID: 18689614.

Jayaratne SD, Atukorale V, Gomes L, Chang T, Wijesinghe T, Fernando S, et al. Evaluation of the WHO
revised criteria for classification of clinical disease severity in acute adult dengue infection. BMC research notes.
2012;5:645. Epub 2012/11/22. doi: 10.1186/1756-0500-5-645. PubMed PMID: 23167997; PubMed Central PMCID:
PMCPMC3534490.

563 48. Suresh SC, Hanumanthaiah R, Ramakrishna C, Sandeep R, Narasimhasetty PS, Ramakrishna V, et al.
564 Serum Ferritin As a Prognostic Indicator in Adult Dengue Patients. The American journal of tropical medicine and
565 hygiene. 2020;104(3):1072-8. Epub 2020/12/30. doi: 10.4269/ajtmh.20-1111. PubMed PMID: 33372649; PubMed
566 Central PMCID: PMCPMC7941811.

49. Rojas A, Cardozo F, Cantero C, Stittleburg V, Lopez S, Bernal C, et al. Characterization of dengue cases
among patients with an acute illness, Central Department, Paraguay. PeerJ. 2019;7:e7852. Epub 2019/10/17. doi:
10.7717/peerj.7852. PubMed PMID: 31616598; PubMed Central PMCID: PMCPMC6790102.

 570 50. Pan American Health Organization. Dengue 2021 [01 July 2022]. Available from: https://www3.paho.org/data/index.php/es/temas/indicadores-dengue.html.

572 51. Lovera D, Martinez-Cuellar C, Galeano F, Amarilla S, Vazquez C, Arbo A. Clinical manifestations of
573 primary and secondary dengue in Paraguay and its relation to virus serotype. Journal of infection in developing
574 countries. 2019;13(12):1127-34. Epub 2020/02/24. doi: 10.3855/jidc.11584. PubMed PMID: 32088700.

575 52. Vázquez C, Villalba S, Gamarra ML, Oviedo E, Oviedo A, Ortega MJ, et al. Características Virológicas y
576 Serológicas de Pacientes con Dengue Grave y Fallecidos por Dengue durante la Epidemia del Año 2011 en
577 Paraguay. Rev Inst Med Trop. 2012;7:8-18.

578 53. Martínez de Cuellar C, Lovera D, Arbo A. Factores de riesgo asociados a mortalidad por Dengue en menores de 15 años. Paraguay, periodo 2010-2013. Pediatr (Asunción). 2017;44(2):136-42.

580 54. Rios González CM. La investigación científica en Dengue, Zika y Chikungunya: evaluación bibliométrica
581 de las contribuciones de la literatura paraguaya. Rev Cient Cienc Med. 2016;19:65.

582 55. Talarico LB, Byrne AB, Amarilla S, Lovera D, Vazquez C, Chamorro G, et al. Characterization of type I
583 interferon responses in dengue and severe dengue in children in Paraguay. Journal of clinical virology : the official
584 publication of the Pan American Society for Clinical Virology. 2017;97:10-7. Epub 2017/10/28. doi:
585 10.1016/j.jcv.2017.10.010. PubMed PMID: 29078078.

586 56. Rojas A, Natrajan MS, Weber J, Cardozo F, Cantero C, Ananta JS, et al. Comparison of Anti-Dengue and
587 Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing. The American journal of tropical
588 medicine and hygiene. 2021. Epub 2021/03/31. doi: 10.4269/ajtmh.20-1449. PubMed PMID: 33782214; PubMed
589 Central PMCID: PMCPMC8103464.

57. Waggoner JJ, Gresh L, Mohamed-Hadley A, Ballesteros G, Davila MJ, Tellez Y, et al. Single-Reaction
Multiplex Reverse Transcription PCR for Detection of Zika, Chikungunya, and Dengue Viruses. Emerging
infectious diseases. 2016;22(7):1295-7. doi: 10.3201/eid2207.160326. PubMed PMID: 27184629; PubMed Central
PMCID: PMC4918162.

58. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Comparison of the FDAapproved CDC DENV-1-4 real-time reverse transcription-PCR with a laboratory-developed assay for dengue virus
detection and serotyping. Journal of clinical microbiology. 2013;51(10):3418-20. doi: 10.1128/JCM.01359-13.
PubMed PMID: 23903549; PubMed Central PMCID: PMC3811623.

598 59. Waggoner JJ, Abeynayake J, Sahoo MK, Gresh L, Tellez Y, Gonzalez K, et al. Single-reaction, multiplex,
599 real-time rt-PCR for the detection, quantitation, and serotyping of dengue viruses. PLoS neglected tropical diseases.
600 2013;7(4):e2116. doi: 10.1371/journal.pntd.0002116. PubMed PMID: 23638191; PubMed Central PMCID:
601 PMC3630127.

602 60. Zhang B, Pinsky BA, Ananta JS, Zhao S, Arulkumar S, Wan H, et al. Diagnosis of Zika virus infection on a nanotechnology platform. Nature medicine. 2017;23(5):548-50. Epub 2017/03/07. doi: 10.1038/nm.4302. PubMed
604 PMID: 28263312.

605 61. Dirección General de Vigilancia de la Salud, Ministerio de Salud Pública y Bienestar Social. Boletín
 606 Epidemiológico: Semana Epidemiológica 52. 2021;(52).

607 62. Lee VJ, Chow A, Zheng X, Carrasco LR, Cook AR, Lye DC, et al. Simple clinical and laboratory
608 predictors of Chikungunya versus dengue infections in adults. PLoS neglected tropical diseases. 2012;6(9):e1786.
609 doi: 10.1371/journal.pntd.0001786. PubMed PMID: 23029573; PubMed Central PMCID: PMC3459852.

610 63. Chadwick D, Arch B, Wilder-Smith A, Paton N. Distinguishing dengue fever from other infections on the
basis of simple clinical and laboratory features: application of logistic regression analysis. Journal of clinical
virology : the official publication of the Pan American Society for Clinical Virology. 2006;35(2):147-53. Epub
2005/08/02. doi: 10.1016/j.jcv.2005.06.002. PubMed PMID: 16055371.

614 64. Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile illnesses
615 in endemic populations. Tropical medicine & international health : TM & IH. 2008;13(11):1328-40. doi:
616 10.1111/j.1365-3156.2008.02151.x. PubMed PMID: 18803612; PubMed Central PMCID: PMC2756447.

617 65. Halstead SB. Dengue in the Americas and Southeast Asia: do they differ? Revista panamericana de salud
618 publica = Pan American journal of public health. 2006;20(6):407-15. PubMed PMID: 17341332.

66. Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The Good, the Bad, and the Shocking: The Multiple
620 Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis. Annu Rev Virol. 2018;5(1):227-53.
621 Epub 2018/07/26. doi: 10.1146/annurev-virology-101416-041848. PubMed PMID: 30044715; PubMed Central
622 PMCID: PMCPMC6311996.

623 67. Jayathilaka D, Gomes L, Jeewandara C, Jayarathna GSB, Herath D, Perera PA, et al. Role of NS1
624 antibodies in the pathogenesis of acute secondary dengue infection. Nat Commun. 2018;9(1):5242. Epub
625 2018/12/12. doi: 10.1038/s41467-018-07667-z. PubMed PMID: 30531923; PubMed Central PMCID:
626 PMCPMC6286345.

627 68. Nguyen THT, Clapham HE, Phung KL, Nguyen TK, TT DI, Nguyen THQ, et al. Methods to discriminate
628 primary from secondary dengue during acute symptomatic infection. BMC infectious diseases. 2018;18(1):375.
629 Epub 2018/08/09. doi: 10.1186/s12879-018-3274-7. PubMed PMID: 30086716; PubMed Central PMCID:
630 PMCPMC6081805.

631 69. Duyen HT, Ngoc TV, Ha do T, Hang VT, Kieu NT, Young PR, et al. Kinetics of plasma viremia and
632 soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune
633 status. The Journal of infectious diseases. 2011;203(9):1292-300. doi: 10.1093/infdis/jir014. PubMed PMID:
634 21335562; PubMed Central PMCID: PMCPMC3069728.

635 70. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, Suntayakorn S, et al. Differing influences of
636 virus burden and immune activation on disease severity in secondary dengue-3 virus infections. The Journal of
637 infectious diseases. 2002;185(9):1213-21. Epub 2002/05/10. doi: 10.1086/340365. PubMed PMID: 12001037.

Nunes PC, Sampaio SA, da Costa NR, de Mendonca MC, Lima Mda R, Araujo SE, et al. Dengue severity
associated with age and a new lineage of dengue virus-type 2 during an outbreak in Rio De Janeiro, Brazil. Journal
of medical virology. 2016;88(7):1130-6. Epub 2016/04/12. doi: 10.1002/jmv.24464. PubMed PMID: 27061403.

641 72. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, et al. Dengue viremia
642 titer, antibody response pattern, and virus serotype correlate with disease severity. The Journal of infectious
643 diseases. 2000;181:2.

644 73. Wang WK, Chao DY, Kao CL, Wu HC, Liu YC, Li CM, et al. High levels of plasma dengue viral load
645 during defervescence in patients with dengue hemorrhagic fever: implications for pathogenesis. Virology.
646 2003;305(2):330-8. Epub 2003/02/08. PubMed PMID: 12573578.

647 74. Wang WK, Chen HL, Yang CF, Hsieh SC, Juan CC, Chang SM, et al. Slower rates of clearance of viral
648 load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clinical infectious
649 diseases : an official publication of the Infectious Diseases Society of America. 2006;43(8):1023-30. Epub
650 2006/09/20. doi: 10.1086/507635. PubMed PMID: 16983615.

75. Nguyen MT, Ho TN, Nguyen VV, Nguyen TH, Ha MT, Ta VT, et al. An Evidence-Based Algorithm for
Early Prognosis of Severe Dengue in the Outpatient Setting. Clinical infectious diseases : an official publication of
the Infectious Diseases Society of America. 2017;64(5):656-63. Epub 2016/12/31. doi: 10.1093/cid/ciw863.
PubMed PMID: 28034883; PubMed Central PMCID: PMCPMC5850639.

76. Nunes PCG, Nogueira RMR, Heringer M, Chouin-Carneiro T, Damasceno Dos Santos Rodrigues C, de
Filippis AMB, et al. NS1 Antigenemia and Viraemia Load: Potential Markers of Progression to Dengue Fatal
Outcome? Viruses. 2018;10(6). Epub 2018/06/16. doi: 10.3390/v10060326. PubMed PMID: 29903980; PubMed
Central PMCID: PMCPMC6024368.

77. Thomas L, Verlaeten O, Cabie A, Kaidomar S, Moravie V, Martial J, et al. Influence of the dengue
serotype, previous dengue infection, and plasma viral load on clinical presentation and outcome during a dengue-2
and dengue-4 co-epidemic. The American journal of tropical medicine and hygiene. 2008;78(6):990-8. PubMed
PMID: 18541782.

78. Tukasan C, Furlan NB, Estofolete CF, Nogueira ML, da Silva NS. Evaluation of the importance of fever
with respect to dengue prognosis according to the 2009 WHO classification: a retrospective study. BMC infectious
diseases. 2017;17(1):6. Epub 2017/01/06. doi: 10.1186/s12879-016-2128-4. PubMed PMID: 28052760; PubMed
Central PMCID: PMCPMC5209937.

667 79. Liu YE, Saul S, Rao AM, Robinson ML, Agudelo Rojas OL, Sanz AM, et al. An 8-gene machine learning
668 model improves clinical prediction of severe dengue progression. Genome Med. 2022;14(1):33. Epub 2022/03/30.
669 doi: 10.1186/s13073-022-01034-w. PubMed PMID: 35346346; PubMed Central PMCID: PMCPMC8959795.

670 80. Guzman MG, Jaenisch T, Gaczkowski R, Hang VTT, Sekaran SD, Kroeger A, et al. Multi-country
671 evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis.
672 PLoS neglected tropical diseases. 2010;4(8):e811.

673